Ozempic vs Wegovy: Same Drug, Different Indications

Ozempic and Wegovy are the same active drug — Semaglutide — manufactured by the same company (Novo Nordisk). The differences are dose ceiling (2 mg vs 2.4 mg weekly), FDA-approved indication (T2D vs chronic weight management), packaging, and insurance-coverage rules. This article covers what's actually different and how to think about which one applies to your situation.

For the broader landscape, see peptides for weight loss and Semaglutide vs Tirzepatide.

Quick verdict table

	Ozempic	Wegovy
Molecule	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA-approved indication	Type 2 diabetes (2017); cardiovascular risk reduction in T2D with CVD	Chronic weight management (2021); cardiovascular risk reduction in overweight/obesity with CVD
Maximum dose	2 mg weekly	2.4 mg weekly
Available doses	0.25, 0.5, 1, 2 mg	0.25, 0.5, 1, 1.7, 2.4 mg
Pen format	Multi-use pen, twist-dial dose	Single-use pen, fixed dose
Typical insurance coverage	T2D criteria	BMI ≥ 30 (or ≥ 27 with comorbidity)
Off-label use opposite indication	Used off-label for weight loss	Used on-label for weight loss

What's actually the same

• The molecule: identical Semaglutide.
• The mechanism: GLP-1 receptor agonism.
• The dosing schedule: once weekly subcutaneous.
• The side-effect profile: GI-dominated, dose-related.
• The cardiovascular outcome benefit (per SELECT trial): now labeled on both.

What's actually different

Dose ceiling

Wegovy goes to 2.4 mg weekly; Ozempic tops out at 2 mg. For weight-loss purposes, the 2.4 mg dose produces the trial weight-loss numbers (~15% at 68 weeks per STEP-1). Patients prescribed Ozempic off-label for weight loss are dose-limited at 2 mg — typically producing somewhat smaller weight loss.

Insurance coverage rules

• Ozempic: Generally covered for T2D. Often excluded from weight-management coverage by insurers because the on-label indication is diabetes, not obesity. Some clinics prescribe Ozempic off-label for weight loss when patients have prediabetes or insulin resistance.
• Wegovy: Covered by an increasing number of plans for the obesity indication. Often requires BMI ≥ 30 or ≥ 27 with comorbidity. Coverage has improved meaningfully through 2024–2026 as employers responded to demand.

Pen format

• Ozempic: Multi-use pen with a dial. Pen is good for 4 doses (one month). Practical for users dialing through the titration schedule on one pen.
• Wegovy: Single-use, single-dose pen at each strength. More waste; less risk of dosing error.

Off-label vs on-label use

• Using Ozempic for weight loss in a patient without T2D is off-label.
• Using Wegovy for weight loss in a patient with obesity is on-label.
• Insurance and pharmacy fulfillment differs accordingly.

What about supply

Both have had supply constraints since 2022. The shortage list status has moved up and down for both. As of mid-2026, supply has broadly normalized but specific dose strengths can still be intermittent.

How to choose

• You have type 2 diabetes (with or without obesity)? Ozempic is the on-label option; Wegovy is technically off-label for the T2D-only indication unless you also meet the obesity criteria.
• You have obesity (BMI ≥ 30) without T2D? Wegovy is the on-label option.
• You have overweight (BMI 27–30) with at least one weight-related comorbidity? Wegovy qualifies; insurance coverage depends on the plan.
• Cost is the binding constraint? Whichever your insurance covers better. Cash-pay differences are negligible (both ~$1,000–$1,400/month list).
• You want the maximum weight-loss effect from Semaglutide? Wegovy 2.4 mg — Ozempic's 2 mg ceiling produces somewhat smaller weight loss.

What about Mounjaro / Zepbound (Tirzepatide)?

Different molecule entirely. See Mounjaro vs Ozempic for that comparison, or Semaglutide vs Tirzepatide for the deeper head-to-head.

What about Rybelsus?

Rybelsus is oral Semaglutide. Same molecule as Ozempic and Wegovy but in pill form with an absorption-enhancer excipient. Lower bioavailability than the injectable; the practical effect is roughly two-thirds of the injectable's weight-loss magnitude at maximum dose. Useful for users who can't or won't inject.

Bottom line

• Same molecule. Two different brand-positioned packages.
• Ozempic for T2D, Wegovy for weight loss — pick by FDA indication and insurance coverage.
• For weight loss specifically, Wegovy reaches a higher dose and is on-label.
• Don't pay cash for one when the other is covered by insurance unless the dose ceiling matters.

Where to go from here

• Semaglutide vs Tirzepatide — head-to-head with the other major option.
• Mounjaro vs Ozempic — brand-level comparison across drugs.
• Peptides for weight loss — pillar.
• Best peptides for fat loss — ranked roundup.
• Peptide therapy cost — pricing breakdown.
• Semaglutide research profile.
• Are peptides safe?, peptide side effects — safety frame.

This is informational, not medical advice.